Skip Nav Destination
Issues
1 March 2019
-
Cover Image
Cover Image
ABOUT THE COVER
Benzyl isothiocyanate (BITC), which is derived from cruciferous vegetables like garden cress, is a promising cancer chemopreventative phytochemical belonging to the isothiocyanate family with in vivo efficacy in chemically-induced as well as in transgenic rodent models of breast cancer. Cancer chemoprevention by BITC is associated with apoptosis induction in breast cancer cells and suppression of self-renewal of breast cancer stem-like cells (bCSC). This mechanistic study demonstrates a protective role for Krüppel-like factor 4 (KLF4)-p21CIP1 axis in bCSC inhibition by BITC. The micrograph image shows immunostaining for KLF4 (red color) in BITC-treated MCF-7 cells in which the nuclei are depicted in blue. Translational implication of the findings of this study is that breast cancer chemoprevention by BITC may be augmented with a combination regimen involving BITC and an inhibitor of KLF4. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
ISSN 1940-6207
EISSN 1940-6215
Issue Sections
Commentary
Research Articles
Simultaneous Measurement of 92 Serum Protein Biomarkers for the Development of a Multiprotein Classifier for Ovarian Cancer Detection
Amy P.N. Skubitz; Kristin L.M. Boylan; Kate Geschwind; Qing Cao; Timothy K. Starr; Melissa A. Geller; Joseph Celestino; Robert C. Bast, Jr.; Karen H. Lu; Joseph S. Koopmeiners
Alpha-Blockers As Colorectal Cancer Chemopreventive: Findings from a Case–Control Study, Human Cell Cultures, and In Vivo Preclinical Testing
Nobumi Suzuki; Ryota Niikura; Sozaburo Ihara; Yohko Hikiba; Hiroto Kinoshita; Naoko Higashishima; Yoku Hayakawa; Atsuo Yamada; Yoshihiro Hirata; Ryo Nakata; Makoto Okamoto; Munetaka Sano; Akifumi Kushiyama; Mari Ichinose; Susan L. Woods; Daniel Worthley; Yasuhiko Iwamoto; Kazuhiko Koike
Letters to the Editor
Expression of Concern
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.